Electroporation (EP)-related technical errors experienced during an HIV vaccine clinical trial conducted in Rwanda and Uganda: lessons learned by Bayingana R, Nanvubya A, Karita E, Nyombayire J, Ingabire R, Chinyenze K, Lehrman J, Schimidt C, Hannaman D, Allen S, Fast P

Tolerability and acceptability of electroporation during a Phase 1 vaccine trial at two sites in Uganda and Rwanda by Mpendo J, Bayingana R, Nanvubya A, Karita E, Ssetaala A, Kiwanuka N, Lehrman J, Schmidt C, Hannaman D, Allen S, Fast P

OA05-01. <it>In vivo </it>electroporation enhances the immunogenicity of ADVAX, a DNA-based HIV-1 vaccine candidate, in healthy volunteers by Park H, Schmidt C, Smith C, Dally L, Clark L, Cheeseman H, Gill DK, Tarragona T, Cox J, Huang Y, Andersen J, Caskey M, Vittorino RM, Boente-Carrera MM, Dugin DP, Gardiner DF, Hannaman D, Schlesinger SJ, Hurley A, Vasan S, Sayeed E, Gilmour J, Fast P, Bernard R, Ho DD

Broad HIV-1 inhibition in vitro by vaccine-elicited CD8+ T cells in African adults by Mutua, G, Farah, B, Langat, R, Indangasi, J, Ogola, S, Onsembe, B, Kopycinski, J, Hayes, P, Borthwick, N, Ashraf, A, Dally, L, Barin, B, Tillander, A, Gilmour, J, De Bont, J, Crook, A, Hannaman, D, Cox, J, Anzala, O, Fast, P, Reilly, M, Chinyenze, K, Jaoko, W, Hanke, T, HIV-CORE 004 study group